NYMC > News and Events > NYMC in the News

Sapience Therapeutics ST-36 Receives Orphan Drug Designation from FDA

March 30, 2017

Sapience Therapeutics Inc., a Scarsdale-based biotechnology company that develops therapeutics to address difficult-to-treat cancers, announced that the U.S. Food and Drug Administration granted the company’s leading candidate, protein-based therapeutic ST-36, orphan drug designation for the treatment of glioma.

NYMC Mention: Sapience Therapeutics Inc., is a client of BioInc@NYMC

Source: The Business Journal